Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

NCT06939036 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to strategic business decisions.

Conditions

Small Cell Lung Cancer Extensive Stage
Merkel Cell Carcinoma

Interventions

DRUG: 225Ac-SSO110 + SoC
DRUG: Atezolizumab
DRUG: Durvalumab
DRUG: Avelumab
DRUG: Pembrolizumab
DRUG: Retifanlimab

Sponsor

Ariceum Therapeutics GmbH